Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for MGNX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 27.96M
March 31, 2026 45.32M
December 31, 2025 -65.99M
September 30, 2025 -20.37M
June 30, 2025 -37.64M
March 31, 2025 9.902M
December 31, 2024 41.47M
September 30, 2024 35.60M
June 30, 2024 47.44M
March 31, 2024 24.79M
December 31, 2023 38.82M
September 30, 2023 -33.52M
June 30, 2023 -113.48M
March 31, 2023 28.10M
December 31, 2022 -5.788M
September 30, 2022 71.95M
June 30, 2022 23.04M
March 31, 2022 -18.48M
December 31, 2021 -13.55M
September 30, 2021 -2.617M
June 30, 2021 13.82M
March 31, 2021 -34.26M
December 31, 2020 -16.08M
September 30, 2020 -43.28M
June 30, 2020 41.01M
Date Value
March 31, 2020 10.56M
December 31, 2019 7.626M
September 30, 2019 -6.372M
June 30, 2019 -10.12M
March 31, 2019 -70.49M
December 31, 2018 45.07M
September 30, 2018 -0.006M
June 30, 2018 -7.811M
March 31, 2018 19.39M
December 31, 2017 8.639M
September 30, 2017 4.464M
June 30, 2017 73.13M
March 31, 2017 -8.357M
December 31, 2016 2.034M
September 30, 2016 -3.163M
June 30, 2016 -56.59M
March 31, 2016 -12.53M
December 31, 2015 -145.69M
September 30, 2015 -2.608M
June 30, 2015 -2.812M
March 31, 2015 -0.997M
December 31, 2014 -1.658M
September 30, 2014 -0.672M
June 30, 2014 -0.7947M
March 31, 2014 -0.4473M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Gilead Sciences, Inc. -10.35B
Xencor, Inc. 85.12M
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M
Anika Therapeutics, Inc. -1.28M